Condition (MeSH)
Intestinal Diseases, Parasitic
ClinicalTrials.gov lists 66 trials for Intestinal Diseases, Parasitic or a narrower condition beneath it. National Institute of Allergy and Infectious Diseases (NIAID) has the most among industry and government lead sponsors, with 9.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
13 of the 66 trials are tagged with Intestinal Diseases, Parasitic itself; the rest are tagged with a narrower condition beneath it.
When did Intestinal Diseases, Parasitic trials start? (23)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 5
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 3 |
| 2025 | 2 |
| 2024 | 4 |
| 2023 | 2 |
| 2022 | 4 |
| 2021 | 3 |
| 2020 | 2 |
| 2018 | 1 |
| 2017 | 1 |
| 2016 | 3 |
Showing 10 of 23 earlier years.
No forecast is made for this condition: it averages 2.8 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Intestinal Diseases, Parasitic trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 4 |
| Phase 1/2 | 2 |
| Phase 2 | 6 |
| Phase 2/3 | 2 |
| Phase 3 | 2 |
| Phase 4 | 6 |
| Not applicable | 17 |
| Observational | 27 |
How many Intestinal Diseases, Parasitic trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 5 |
| Active, not recruiting | 2 |
| Completed | 37 |
| Terminated | 7 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Intestinal Diseases, Parasitic trials? (8)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | 9 |
| Pfizer | 4 |
| Novartis Pharmaceuticals | 3 |
| Janssen, LP | 2 |
| Research Institute of Epidemiology, Microbiology and Infectious Diseases, Uzbekistan | 2 |
Showing 5 of 8 sponsors.
Which drugs are being tested for Intestinal Diseases, Parasitic? (3)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Nitazoxanide | 6 |
| Paromomycin | 3 |
| Albendazole | 2 |
Interventions as named in the registry (12)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Metronidazol | 5 |
| 1% Azithromycin | 3 |
| Cryptosporidium parvum oocysts (ABO809) | 2 |
| Cryptosporidium Immune Whey Protein Concentrate (Bovine) | 2 |
| Spiramycin | 2 |
Showing 5 of 12 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Intestinal Diseases, Parasitic trials report? (9)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Disseminated intravascular coagulation | 2 | 1 |
| Liver disorder | 2 | 1 |
| Acute respiratory distress syndrome | 1 | 1 |
| Bronchopulmonary aspergillosis | 1 | 1 |
| Cholecystitis acute | 1 | 1 |
Showing 5 of 9 adverse events.
Which publications cover Intestinal Diseases, Parasitic? (56)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Evaluating impacts of improved flooring on enteric and parasitic infections in rural households in Kenya: study protocol for a cluster-randomised controlled trial. | BMJ open | 2025 | Yes |
| "Our desire is to make this village intestinal worm free": Identifying determinants of high coverage of community-wide mass drug administration for soil transmitted helminths in Benin, India, and Malawi. | PLoS neglected tropical diseases | 2024 | Yes |
| Effect of mass deworming with antihelminthics for soil-transmitted helminths during pregnancy. | The Cochrane database of systematic reviews | 2021 | Yes |
| Pityriasis alba: Possible associations with intestinal helminths and pathogenic protozoa. | International journal of clinical practice | 2020 | Yes |
| Associations between intestinal parasitic infections, anaemia, and diarrhoea among school aged children, and the impact of hand-washing and nail clipping. | BMC research notes | 2020 | Yes |
Showing 5 of 56 publications.
Sub-conditions in MeSH (6)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.